Orchard Therapeutics (Nasdaq:ORTX) - Aktienkurs, Nachrichten und Analyse

ORTX Aktienübersicht

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany.

Über das Unternehmen

ORTX grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	4/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 34.51%

Die Erträge sind in den letzten 5 Jahren um 12.3% pro Jahr gestiegen.

Risikoanalyse

Die Aktionäre wurden im vergangenen Jahr erheblich verwässert

Hat weniger als 1 Jahr Cash Runway

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Orchard Therapeutics plc Wettbewerber

Adaptimmune Therapeutics

NasdaqGS:ADAP

US$239.6m

Mersana Therapeutics

NasdaqGS:MRSN

US$226.9m

AC Immune

NasdaqGM:ACIU

US$366.1m

Foghorn Therapeutics

NasdaqGM:FHTX

US$535.6m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Orchard Therapeutics
Historische Aktienkurse
Aktueller Aktienkurs	US$16.70
52-Wochen-Hoch	US$16.72
52-Wochen-Tief	US$4.24
Beta	0.55
11 Monat Veränderung	1.71%
3 Monate Veränderung	4.57%
1 Jahr Veränderung	188.88%
33 Jahre Veränderung	-70.28%
5 Jahre Veränderung	-86.41%
Veränderung seit IPO	-88.07%

Aktuelle Nachrichten und Updates

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Jan 19

Recent updates

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Jan 19

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Aug 04

Orchard Therapeutics: Shadow Of Former Glory

Jan 20

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Aug 16

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Jun 14

What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Feb 03

Orchard Therapeutics appoints Braden Parker as chief commercial officer

Jan 29

Orchard Therapeutics' OTL-200 wins FDA's RMAT status

Jan 14

Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022

Jan 12

Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Jan 08

Orchard Therapeutics' MLD gene therapy wins European nod

Dec 21

Our View On Orchard Therapeutics

Dec 17

Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Dec 11

Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study

Dec 08

Orchard Therapeutics (ORTX) Investor Presentation - Slideshow

Nov 22

Aktionärsrenditen

	ORTX	US Biotechs	US Markt
7D	0.9%	-3.0%	0.9%
1Y	188.9%	19.2%	32.4%

Rendite im Vergleich zur Industrie: ORTX übertraf die Branche US Biotechs, die im vergangenen Jahr eine Rendite von 7.4 erzielte.

Rendite vs. Markt: ORTX übertraf den Markt US, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is ORTX's price volatile compared to industry and market?
ORTX volatility
ORTX Average Weekly Movement	0.6%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Stabiler Aktienkurs: ORTX hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: ORTXDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 16% auf 1% zurückgegangen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2015	166	Bobby Gaspar	www.orchard-tx.com

Orchard Therapeutics plc's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Orchard Therapeutics im Vergleich zum Marktanteil des Unternehmens?
ORTX grundlegende Statistiken
Marktanteil	US$380.12m
Gewinn(TTM)	-US$72.92m
Umsatz(TTM)	US$21.84m

17.4x

Kurs-Umsatz-Verhältnis

-5.2x

Kurs-Gewinn-Verhältnis

Ist ORTX zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ORTX Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$21.84m
Kosten der Einnahmen	US$79.52m
Bruttogewinn	-US$57.68m
Sonstige Ausgaben	US$15.24m
Umsatz	-US$72.92m

Zuletzt gemeldete Gewinne

Sep 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-3.20
Bruttomarge	-264.11%
Nettogewinnspanne	-333.90%
Schulden/Eigenkapital-Verhältnis	31.9%

Wie hat sich ORTX auf lange Sicht entwickelt?

Historische Performance und Vergleiche

ORTX Aktienübersicht

Belohnungen

Risikoanalyse

Orchard Therapeutics plc Wettbewerber

NasdaqGS:ADAP

US$239.6m

NasdaqGS:MRSN

US$226.9m

NasdaqGM:ACIU

US$366.1m

NasdaqGM:FHTX

US$535.6m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel)

Orchard Therapeutics Files Form 15

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Recent updates

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel)

Orchard Therapeutics Files Form 15

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Orchard Therapeutics plc(NasdaqCM:ORTX) dropped from NASDAQ Composite Index

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

New major risk - Financial position

Orchard Therapeutics Receives Swiss Agency for Therapeutic Products Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy

Orchard Therapeutics plc Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH

Orchard Therapeutics plc, Annual General Meeting, Dec 19, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-Of-Concept Study of Otl-203 in Mps-Ih At Esgct 2023

Price target decreased by 25% to US$16.00

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

New major risk - Share price stability

Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in Metachromatic Leukodystrophy and Receives Priority Review

Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 Bla in MLD At the Ssiem Annual Symposium 2023

Consensus estimates of losses per share improve by 55%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 30%

Consensus EPS estimates upgraded to US$1.61 loss

Consensus EPS estimates upgraded to US$1.81 loss

Consensus revenue estimates decrease by 18%, EPS upgraded

Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

Price target decreased by 28% to US$21.60

Price target decreased by 8.7% to US$27.40

Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Indapta Therapeutics Appoints Moya Daniels as Senior Vice President of Regulatory, Quality and Clinical Operations

Orchard Therapeutics plc Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-Of-Concept Study of OTL-201 in Mps-IIIA

Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

Price target decreased to US$3.67

Insufficient new directors

Orchard Therapeutics: Gene Therapy For Rare Child Disease

Consensus forecasts updated

Price target decreased to US$3.67

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Price target decreased to US$3.67

Price target decreased to US$4.00

Insufficient new directors

Orchard Therapeutics Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates increase by 37%

Price target decreased to US$8.64

Orchard Therapeutics plc Announces Publication in the Lancet of Long-Term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-Onset MLD

Orchard Therapeutics: Shadow Of Former Glory

Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones

Consensus forecasts updated

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.20 loss in 3Q 2020)

Price target decreased to US$10.31

Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event

Consensus forecasts updated

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Consensus forecasts updated

Price target decreased to US$11.70

Orchard Therapeutics plc announced that it expects to receive $7.5 million in funding from Pharming Group N.V.

Orchard Therapeutics plc Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs

Price target decreased to US$13.00

Erträge & Einnahmen